The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics von Amin, Dhara N., Campbell, Marcia R., Moasser, Mark M.

Volltext

HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells von Amin, Dhara N, Sergina, Natalia, Lim, Lionel, Goga, Andrei, Moasser, Mark M

Volltext

Id2 Promotes Tumor Cell Migration and Invasion through Transcriptional Repression of Semaphorin 3F von COMA, Silvia, AMIN, Dhara N, SHIMIZU, Akio, LASORELLA, Anna, IAVARONE, Antonio, KLAGSBRUN, Michael

Volltext

Disentangling multidimensional spatio-temporal data into their common and aberrant responses von Chang, Young Hwan, Korkola, James, Amin, Dhara N, Moasser, Mark M, Carmena, Jose M, Gray, Joe W, Tomlin, Claire J

Volltext

Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors von AMIN, Dhara N, HIDA, Kyoko, BIELENBERG, Diane R, KLAGSBRUN, Michael

Volltext

Tumor-associated endothelial cells with cytogenetic abnormalities von HIDA, Kyoko, HIDA, Yasuhiro, AMIN, Dhara N, FLINT, Alan F, PANIGRAHY, Dipak, MORTON, Cynthia C, KLAGSBRUN, Michael

Volltext

Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study... von Lasater, Elisabeth A., Amin, Dhara N., Bannerji, Rajat, Mali, Raghuveer Singh, Barrett, Kathy, Rys, Ryan N., Oeh, Jason, Lin, Eva, Sterne‐Weiler, Tim, Ingalla, Ellen Rei, Go, MaryAnn, Yu, Shang‐Fan, Krem, Maxwell M., Arthur, Chris, Hahn, Uwe, Johnston, Anna, Karur, Vinit, Khan, Nadia, Marlton, Paula, Phillips, Tycel, Gritti, Giuseppe, Seymour, John F., Tani, Monica, Yuen, Sam, Martin, Scott, Chang, Matthew T., Rose, Christopher M., Pham, Victoria C., Polson, Andrew G., Chang, YiMeng, Wever, Claudia, Johnson, Nathalie A., Jiang, Yanwen, Hirata, Jamie, Sampath, Deepak, Musick, Lisa, Flowers, Christopher R., Wertz, Ingrid E.

Volltext

A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers von Amin, Dhara N, Ahuja, Deepika, Yaswen, Paul, Moasser, Mark M

Volltext

Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin von Campbell, Marcia R., Zhang, Hui, Ziaee, Shabnam, Ruiz-Saenz, Ana, Gulizia, Nathaniel, Oeffinger, Julie, Amin, Dhara N., Ahuja, Deepika, Moasser, Mark M., Park, Catherine C.

Volltext

Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib von Amin, Dhara N, Ruiz-Saenz, Ana, Gulizia, Nathaniel, Moasser, Mark M

Volltext

Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells von Amin, Dhara N., Bielenberg, Diane R., Lifshits, Eugene, Heymach, John V., Klagsbrun, Michael

Volltext

Neuregulin-regulated gene expression in mammary carcinoma cells von Amin, Dhara N., Tuck, David, Stern, David F.

Volltext

Gene expression profiling of ErbB receptor and ligand-dependent transcription von AMIN, Dhara N, PERKINS, Archibald S, STERN, David F

Volltext

A TORC2-Akt feedforward topology underlies HER3 resiliency in HER2-amplified cancers von Amin, Dhara N., Ahuja, Deepika, Yaswen, Paul, Moasser, Mark M.

Volltext

Abstract 880: Anti-tubulin antibody drug conjugates potentiate venetoclax activity in non-Hodgkin lymphoma by targeting MCL-1 von Amin, Dhara N., Oeh, Jason, Zindal, Anuradha, Musick, Lisa, Hirata, Jamie, Mobasher, Mehrdad, Polson, Andy, Sampath, Deepak, Wertz, Ingrid E.

Volltext

Abstract CT133: Targeting BCL-2 and MCL-1 overcomes treatment resistance in relapsed and refractory non-Hodgkin lymphoma: Pre-clinical rationale and results from an open-label phas... von Amin, Dhara N., Bannerji, Rajat, Mali, Raghuveer Singh, Oeh, Jason, Lin, Eva, Zindal, Anuradha, Go, MaryAnn, Yu, Shang-Fan, Krem, Maxwell, Arthur, Chris, Hahn, Uwe, Johnston, Anna M., Karur, Vinit G., Khan, Nadia, Marlton, Paula, Phillips, Tycel, Gritti, Giuseppe, Seymour, John F., Tani, Monica, Yuen, Sam Yuen, Martin, Scott, Chang, Matthew T., Rose, Christopher M., Pham, Victoria C., Lasater, Elizabeth A., Polson, Andrew G., Chang, YiMeng, Hirata, Jamie, Musick, Lisa, Sampath, Deepak, Flowers, Christopher R., Wertz, Ingrid E.

Volltext

Effective treatment of HER2-amplified breast cancer by targeting HER3 and [beta]1 integrin von Campbell, Marcia R, Zhang, Hui, Ziaee, Shabnam, Ruiz-Saenz, Ana, Gulizia, Nathaniel, Oeffinger, Julie, Amin, Dhara N, Ahuja, Deepika, Moasser, Mark M, Park, Catherine C

Volltext

Abstract 3043: Akt-mTorc2 signaling underlies cellular addiction to HER3 signaling in HER2-amplified cancers von Amin, Dhara N., Ahuja, Deepika, Ducker, Gregory S., Yaswen, Paul, Shokat, Kevan, Moasser, Mark

Volltext

Abstract 1653: Highly effective treatment of HER2-amplified breast cancers through the complete inactivation of the HER2-HER3 tumorigenic driver von Amin, Dhara N., Sergina, Natalia, Ahuja, Deepika, McMahon, Martin, Wang, Donghui, Hann, Byron, Shokat, Kevan, Moasser, Mark M.

Volltext

Disentangling Multidimensional Spatio-Temporal Data into Their Common and Aberrant Responses: e0121607 von Chang, Young Hwan, Korkola, James, Amin, Dhara N, Moasser, Mark M, Carmena, Jose M, Gray, Joe W, Tomlin, Claire J

Volltext